Overview
- Regulators posted notices Wednesday that identify the affected lot as 3 mg extended‑release tablets in 60‑count bottles, Lot 8177156, with a Feb. 28, 2027 expiration, and confirm the FDA’s Class II status.
- Tests found the lot failed dissolution standards, which means the tablets may not release alprazolam at the intended rate and could change how much medicine a patient absorbs over time.
- Viatris initiated the voluntary recall on March 17 and says about 51 bottles went to U.S. wholesalers, with no reports of adverse reactions so far.
- The California State Board of Pharmacy told patients who have this lot to stop using it, while FDA and Viatris say patients should consult their pharmacist or prescriber as pharmacies and wholesalers handle returns.
- The recalled bottles were distributed nationwide between Aug. 27, 2024 and May 29, 2025, a key detail for patients who rely on steady dosing to manage anxiety or panic symptoms and need to check labels for the lot number.